MY ACCOUNT | NEWSLETTER |

Effects of brotizolam as a co-agent with ketamine for induction of anesthesia in calves

Brotizolam IV at 2 /kg worsened induction quality of anesthesia with ketamine


Anesthesia in food producing animals in the EU and UK is legally limited to a narrow choice of drugs, the only licensed benzodiazepine being brotizolam. The aim of this study was to investigate the effects of brotizolam as a co-agent with ketamine on the quality of induction, intubation, muscle relaxation and recovery from isoflurane anesthesia.

Seventeen calves were enrolled in this prospective, blinded, randomized experimental study. Calves were sedated with 0.05 mg/kg xylazine and 0.1 mg/kg butorphanol IV. After assessing the quality of sedation, anesthesia was induced with 2 mg/kg ketamine (group KETA) or 2 mg/kg ketamine with 2 μg/kg brotizolam IV (group BROTI).

An additional 1 mg/kg ketamine was administered via IV every two min until intubation was possible. Anesthesia was maintained with isoflurane in a mixture of oxygen and air. The amount of ketamine required, quality of induction, intubation, muscle relaxation, and recovery were scored and compared between groups using ordinal regression models (P < 0.05 was considered statistically significant). 

Sedation scores did not differ significantly between groups but were positively associated with the quality of recovery (P = 0.0098). Group BROTI was associated with a lower quality of induction (P < 0.0001), intubation (P = 0.0203) and muscle relaxation (P = 0.0043). The sedation score and treatment had no effect on the number of attempts of intubation, additional ketamine doses, time to extubation and recovery time. 

Brotizolam had a negative effect on the quality of induction, intubation, and muscle relaxation compared to ketamine alone. In conclusion, the authors do not recommend using brotizolam under these circumstances.

O. d'Anselme et al. “Effects of brotizolam as a co-agent with ketamine for induction of anaesthesia in calves.” Vet J. 2023 Mar; 293:105957. doi: 10.1016/j.tvjl.2023.105957.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats

Like0
Dislike0

Additive manufacturing to veterinary practice: Recovery of bony defects after the osteosarcoma resection in canines

Like0
Dislike0

Antimicrobial drug use in poultry

Like0
Dislike0

New hope and compassionate care for animal patients in pain

Like0
Dislike0

Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top